Bose 1990.

Methods	Randomized Multicenter Blinding of randomization: yes Blinding of intervention: Attempted (infants treated in screened area by special drug administration team who did not participate in subsequent care) Complete follow‐up: yes Blinding of outcome measurement: yes Stratification by birthweight (700‐1000g, 1001‐1350g) and gender Long‐term follow‐up: Corbet (1995), Kraybill (1995) 80% of survivors evaluated
Participants	Premature infants Inborn Birthweight 700‐1350 grams No proven lung maturity No fetal anomaly or chromosomal abnormality No fetal growth retardation No evidence of hydrops fetalis No proven chorioamnionitis No maternal heroin addiction Infants randomized: Exosurf = 192 Air Placebo = 193
Interventions	Intubation and intratracheal administration of Exosurf Neonatal (5ml/kg) as soon after birth as possible or intubation and sham air treatment
Outcomes	PRIMARY OUTCOME: Survival at 28 days of age without bronchopulmonary dysplasia SECONDARY OUTCOMES: Ventilatory requirements Respiratory distress syndrome Complications of prematurity FOLLOW‐UP: Assessed at 1 and 2 years adjusted age
Notes	Evaluation of BPD, neonatal mortality does not include infants with congenital malformation or congenital pneumonia
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Stratification by birthweight (700 to 1000 g, 1001 to 1350 g) and gender
Allocation concealment?	Low risk	Blinding of randomization: yes
Blinding? All outcomes	Low risk	Blinding of intervention: Attempted (infants treated in screened area by special drug administration team who did not participate in subsequent care) Blinding of outcome measurement: yes
Incomplete outcome data addressed? All outcomes	Low risk	Complete follow‐up: yes Long‐term follow‐up: Corbet (1995), Kraybill (1995) 80% of survivors evaluated
Free of selective reporting?	Low risk
Free of other bias?	Low risk